The self-adjuvanting peptide vaccine conjugated with TLR7 agonists is a novel form of vaccine that has the potential to be applied for COVID-19 or other infectious diseases and can serve as a rapid response strategic reserve for future outbreaks. This evidence concerns the gene TLR7 and COVID-19.